Candel Therapeutics said new digital pathology data show aglatimagene activates immune responses in localized prostate cancer. The company said the analyses support clinical benefit seen in its phase 3 trial, marking progress for the program.
published
Candel Therapeutics said new digital pathology data show aglatimagene activates immune responses in localized prostate cancer. The company said the analyses support clinical benefit seen in its phase 3 trial, marking progress for the program.
Latest documented BWB result
BWB member result
Exit /ES with a 14 Pt (56 tick) profit
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.